tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Lauzurica R et al. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus. 2007 Transplant. Proc. pmid:17889127
Charpentier B Induction versus non-induction protocols in anti-calcineurin-based immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750425
Miura S et al. Long-term results of spousal renal donor transplants with donor-specific blood transfusions. 2001 Nov-Dec Transplant. Proc. pmid:11750463
Christiaans M et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. 1998 Transplant. Proc. pmid:9636516
Sato S et al. Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. 1998 Transplant. Proc. pmid:9636517
Gavela E et al. Histological findings of early graft biopsies in old donor renal transplant patients receiving induction therapy. 2009 Jul-Aug Transplant. Proc. pmid:19715842
Wang SS et al. Clinical experience of tacrolimus with everolimus in heart transplantation. 2012 Transplant. Proc. pmid:22564581
Smoter P et al. Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience. 2014 Transplant. Proc. pmid:25380918
Ricordi C et al. Donor bone marrow cell infusion without recipient cytoablation induces acceptance of rat islet allografts. 1994 Transplant. Proc. pmid:7527967
Nazmul MN et al. Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report. 2017 Transplant. Proc. pmid:29198681
Tsugita M et al. Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. 1994 Transplant. Proc. pmid:7527969
Jang HJ et al. Conversion from cyclosporine to tacrolimus in renal allograft recipients with delayed graft function from severe acute tubular necrosis. 2000 Transplant. Proc. pmid:11119904
Kuroki H et al. Effect of FK 506 and donor-specific blood transfusion on the rat composite tissue limb allograft and the mechanism of long-term graft survival. 1993 Transplant. Proc. pmid:7679833
Machida M et al. Effect of temperature and hematocrit on plasma concentration of FK 506. 1991 Transplant. Proc. pmid:1721266
Ko S et al. Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation. 1996 Transplant. Proc. pmid:8623229
Rajnoch J et al. Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: effect of tacrolimus. 2005 Jan-Feb Transplant. Proc. pmid:15808641
Sahar G et al. Glucose metabolism in heart transplant recipients treated with FK506 or cyclosporine. 2003 Transplant. Proc. pmid:12644092
Zeevi A et al. Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. 1990 Transplant. Proc. pmid:1689902
Sgrosso JL et al. Tacrolimus pharmacokinetics in heart transplant. 2002 Transplant. Proc. pmid:11959225
Langrehr JM et al. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. 1998 Transplant. Proc. pmid:9636583
Boran M et al. Determining renal resistive and pulsatility indexes long-term after kidney transplantation in kidney transplant recipients on cyclosporine a-, tacrolimus-, or sirolimus-based regimens. 2014 Transplant. Proc. pmid:24935296
Yoshida S et al. Combination therapy with FK 506 and RS61443 for rejection following allogeneic small bowel transplantation in rats. 2000 Transplant. Proc. pmid:11120262
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunologic risk". 2000 Transplant. Proc. pmid:11120281
McKenna BA et al. Tacrolimus (FK 506): a whole blood assay as measured on the Abbott IMx analyzer. 1996 Transplant. Proc. pmid:8623491
Jordan ML et al. Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up. 1999 Transplant. Proc. pmid:10576052
Tanida I et al. Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. 1991 Transplant. Proc. pmid:1721297
Woodle ES et al. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. 1999 Transplant. Proc. pmid:10576053
Kolonko A et al. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation. 2011 Transplant. Proc. pmid:21996198
Kurnatowska I et al. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. 2011 Transplant. Proc. pmid:21996199
Orita T et al. Effect of FK 506 in combination with prednisolone on the graft-vs-host reaction after small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7518147
Ge J et al. Impact of FOXP3 Polymorphisms on the Blood Level of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:27569929
Masuda S et al. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. 2005 Transplant. Proc. pmid:15919446
Tada H et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. 2005 Transplant. Proc. pmid:15919447
Graeb C et al. Cytoimmunologic monitoring of small bowel allograft recipients. 1992 Transplant. Proc. pmid:1376515
Fay JW et al. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. 1995 Transplant. Proc. pmid:7533383
Liu B et al. Single-center experience: tacrolimus and mycophenolate mofetil in early stage of kidney transplantation with liver dysfunction. 2003 Transplant. Proc. pmid:12591396
Yang SS et al. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). 2015 Transplant. Proc. pmid:25891697
Takai K et al. Immunosuppressive effects of FK 506 on rat lymphoid organs. 1991 Transplant. Proc. pmid:1721329
Ogino S et al. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients. 2004 Transplant. Proc. pmid:15041357
Hassoun Z et al. The choice of calcineurin inhibitor does not influence centrilobular necrosis after orthotopic liver transplantation. 2002 Transplant. Proc. pmid:12176464
Opelz G Evaluation of immunosuppressive induction regimens in renal transplantation. Collaborative Transplant Study. 1998 Transplant. Proc. pmid:9865286
Moffatt SD et al. Comparative efficacy of liposomal FK506 with FK506. 1998 Transplant. Proc. pmid:9865297
Malyszko J et al. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. 2009 Transplant. Proc. pmid:19857675
Zegarska J et al. Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients. 2016 Transplant. Proc. pmid:27496443
Spada M et al. Tacrolimus and mycophenolate mofetil in pig small bowel transplantation: different protocols and their outcome. 1997 Transplant. Proc. pmid:9142286
Ronchetti F et al. Intestinal damage evaluation in swine allograft small bowel through hyaluronic acid quantification. 1997 Transplant. Proc. pmid:9142293
Weber M et al. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. 1997 Transplant. Proc. pmid:9414883
Gelens MA et al. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus? 2005 Transplant. Proc. pmid:15919498
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
Shapiro R et al. FK 506 in clinical kidney transplantation. 1991 Transplant. Proc. pmid:1721361
Todo S et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. 1991 Transplant. Proc. pmid:1703340
McCauley J et al. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. 1991 Transplant. Proc. pmid:1721362
Jiménez O et al. Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation. 2003 Transplant. Proc. pmid:12962758
Zeevi A et al. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. 1991 Transplant. Proc. pmid:1703341
Teebken OE et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients. 2002 Transplant. Proc. pmid:12072335
Burke GW et al. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection. 2002 Transplant. Proc. pmid:12176505
Feitoza CQ et al. A role for HO-1 in renal function impairment in animals subjected to ischemic and reperfusion injury and treated with immunosuppressive drugs. 2007 Transplant. Proc. pmid:17362747
Goh BL and Tan SY FK506 "rescue" therapy complicated by renal tubular acidosis in renal allograft recipients. 1998 Transplant. Proc. pmid:9838575
Tacrolimus in renal transplantation: a comparison of induction vs noninduction therapy (triple therapy): three-month results. 1999 Feb-Mar Transplant. Proc. pmid:10083131
Villanueva ME et al. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation. 2008 Transplant. Proc. pmid:18790198
Meiser BM et al. Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123150
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Carroll PB et al. Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. 1991 Transplant. Proc. pmid:1721394
Gerhardt U et al. High QT dispersion in tacrolimus-treated kidney transplant recipients. 2001 Transplant. Proc. pmid:11377482
Toda F et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. 2002 Transplant. Proc. pmid:12176555
Hesse CJ et al. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. 2001 Transplant. Proc. pmid:11377487
Uchida K et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. 2002 Transplant. Proc. pmid:12176556
Lauro A et al. Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation. 2007 Transplant. Proc. pmid:17580204
Wu MS et al. Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. 1999 Feb-Mar Transplant. Proc. pmid:10083527
Zhou J et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. 2008 Transplant. Proc. pmid:19100435
Morrissey PE et al. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. 2005 Transplant. Proc. pmid:15964334
Lemahieu WP et al. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. 2005 Transplant. Proc. pmid:15964336
Tahir W et al. Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation. Transplant. Proc. pmid:25645795
Murase N et al. Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721424
Takeda M et al. Pretreatment with splenectomy and FK506 in xeno-lung transplantation. 1996 Transplant. Proc. pmid:8658728
Tanaka H et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445067
Wiseman AC et al. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience. 2003 Transplant. Proc. pmid:12742482
Moura Neto A et al. Frequency of Thyroid Dysfunction in Patients With Diabetes Mellitus Before and After Liver Transplantation. 2018 Transplant. Proc. pmid:29661439
Webb NJ et al. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. 2002 Transplant. Proc. pmid:12176639
Koc-Zorawska E et al. Vascular adhesion protein-1, a novel molecule, in kidney and heart allograft recipients. 2013 Transplant. Proc. pmid:23769096
Evans NJ et al. The expression of endothelin and inducible nitric oxide synthase in human renal allografts and their role in chronic renal allograft nephropathy. 2001 Feb-Mar Transplant. Proc. pmid:11267247
Jonas S et al. Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation. 1998 Transplant. Proc. pmid:9723433
Dutta S et al. Liposomal tacrolimus and intestinal drug concentration. 1998 Transplant. Proc. pmid:9745533
Pankewycz O et al. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. 2011 Transplant. Proc. pmid:21440749
Laftavi MR et al. The role of antibiotic prophylaxis in the new era of immunosuppression. 2011 Transplant. Proc. pmid:21440753
Yoshimura R et al. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7524223
Kupferman JC et al. Activation of the renal renin-angiotensin system by cyclosporine A and FK 506 in the rat. 1994 Transplant. Proc. pmid:7524224
Mochizuki M et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. 1991 Transplant. Proc. pmid:1721456
Dalgic A et al. Liver transplantation and tacrolimus monotherapy for hepatocellular carcinoma with expanded criteria. 2005 Transplant. Proc. pmid:16213334
Roat MI et al. Treatment of Cogan's syndrome with FK 506: a case report. 1991 Transplant. Proc. pmid:1721457
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Ochiai T et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. 1987 Transplant. Proc. pmid:2484094
Lee CM et al. Monotherapy with tacrolimus for heart and liver transplant: a case report. 2014 Transplant. Proc. pmid:24767396
Kahl A et al. Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil. 2001 Feb-Mar Transplant. Proc. pmid:11267473
Sessa A et al. Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged-release tacrolimus. 2012 Transplant. Proc. pmid:22974866
Umbro I et al. Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients. 2012 Transplant. Proc. pmid:22974867
Rieber J et al. Effects of tacrolimus and cyclosporine on the coronary microcirculation after heart transplantation: a prospective study with serial intracoronary flow measurements. 1998 Transplant. Proc. pmid:9636446
Kanatani T et al. Experimental limb transplantation, part III: induction of tolerance in the rigorous strain combination of Brown Norway donor to Lewis recipient. 2004 Transplant. Proc. pmid:15686745
Katayama Y et al. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. 1991 Transplant. Proc. pmid:1703690